Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur Mustard
涡轮滴眼液治疗硫芥引起的眼部毒性和失明
基本信息
- 批准号:10480748
- 负责人:
- 金额:$ 74.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdverse effectsAffectAlkylating AgentsAnatomyAngiogenic FactorAntidotesBasement membraneBiological AssayBlindnessCitiesClinicalClinical PathologyCollagen FibrilConsultCorneaCorneal InjuryCorneal UlcerDataDevelopmentDiagnostic ImagingDoseDropsElectron MicroscopyEnzyme-Linked Immunosorbent AssayEpithelialEuthanasiaExtracellular Matrix DegradationEyeEye InjuriesEyedropsFDA approvedFibrosisFluoresceinFormulationFrequenciesFunctional disorderFundingGeneric DrugsGoalsGrantHealthHistologicHumanImmunofluorescence ImmunologicIn VitroInflammationInflammatoryInflammatory ResponseIntellectual PropertyIranIraqJointsKansasKeratopathyLeadLettersLiteratureMagnetic Resonance ImagingMeasuresMediatingMethodsMicroscopeModelingMolecularMonitorMustard GasOcular PathologyOphthalmic SolutionsOphthalmic examination and evaluationOphthalmologistOrgan Culture TechniquesOryctolagus cuniculusPainPathologyPathway interactionsPatientsPersonsPharmaceutical PreparationsPilot ProjectsProcessProductionProperty RightsPublicationsPublishingRecurrenceRegimenResearchSafetyScheduleScientistSecureSyriaTechniquesTechnologyTemperatureTerrorismTestingTherapeutic EffectTimeTissuesToxic effectTransmission Electron MicroscopyTreatment ProtocolsVesicantsVeterinariansVisionWarWestern BlottingWorld War Ibasebench to bedsidecorneal epitheliumdiagnostic tooldrug developmenteffective therapyefficacious treatmenthigh riskin vivoin vivo evaluationlimbalmedical countermeasuremeetingsmultimodalityneovascularizationnovelside effectstem cellstherapeutically effectivetomographytonometryvapor
项目摘要
ABSTRACT
Sulfur mustard gas (SM), a vesicating and warfare agent, has been used in many wars since World War I; most
recently in Syria. SM rapidly penetrates the eye on contact and causes blindness by injuring corneal tissue-
organization and function. Clinically, patients show a pathology termed as Mustard Gas Keratopathy that involves
severe ocular inflammation, recurrent epithelial-erosions, epithelial-stromal separation limbal stem cell
deficiency, corneal ulceration, haze and neovascularization. MGK pathophysiology is biphasic including acute
and delayed-onset, and involves multiple mechanisms. We developed a novel, multimodal, non-steroidal topical
ophthalmic drops, Turbo Eye Drop (TED), containing 4 FDA-approved generic drugs with differing mode of
action, and stable at ambient temperature. Our pilot studies found that topical TED efficaciously treats acute and
delayed-onset MGK in rabbits in vivo and human cornea ex vivo without significant side effects. Our central
hypothesis is that topical TED treats acute and delayed-onset MGK in vivo by curbing SM-induced early
inflammatory responses, extracellular matrix degradation, and production of excessive pro-fibrotic and pro-
angiogenic factors without significant side effects. This project tests two novel hypotheses to establish an
efficacious and safe topical therapy for acute and delayed-onset MGK in vivo, using four specific aims: Aim-1
defines TED treatment for acute MGK in vivo by testing the hypothesis that increasing frequency and duration
of TED application will potently treat acute MGK and blindness without significant side effects. Aim-2 establishes
TED treatment for delayed-onset MGK in vivo by testing the hypothesis that low TED topical dosing for longer
duration will effectively cure delayed-onset MGK without issues in rabbits. Aim-3 uncovers mechanisms used by
TED in mitigating acute and delayed-onset MGK in vivo and in vitro. Aim-4 secures intellectual property rights,
develops regulatory strategies, and advances TED topical ophthalmic drops as an antidote for SM-induced
ocular injury towards human application. This will be accomplished using an established SM-vapor rabbit in vivo
and human cornea organ culture ex vivo models, GMP-grade TED eye drops, and monitoring eyes in live rabbits
in a time-dependent manner with clinical eye exams and diagnostic imaging. The characterization of
mechanisms used by TED in mitigating MGK will be studied using corneal tissues collected after euthanasia by
measuring integrity of corneal epithelial basement membrane, epithelial-stromal organization, and collagen fibril
arrangement using qPCR, ELISAs, immunofluorescence, H&E, and transmission electron microscopy
techniques utilizing our published methods. Successful completion of the project will lead to the development of
an effective and safe therapy for acute and delayed MGK and medical countermeasure to minimize ocular
obliteration caused by the accidental or intentional use of SM in humans, and therefore will have very high impact
in field and public safety.
摘要
硫芥子气(SM)是一种起泡剂和战剂,自第一次世界大战以来已被用于许多战争;
最近在叙利亚。SM在接触后迅速穿透眼睛,并通过损伤角膜组织导致失明-
组织和功能。临床上,患者表现出被称为芥子气角膜病变的病理学,
严重眼部炎症,复发性上皮糜烂,上皮-基质分离,角膜缘干细胞
缺乏、角膜溃疡、混浊和新生血管形成。MGK病理生理学是双相的,包括急性
和延迟发病,涉及多种机制。我们开发了一种新型的,多模式的,非甾体局部
滴眼液,Turbo Eye Drop(TED),含有4种FDA批准的仿制药,
作用,在环境温度下稳定。我们的初步研究发现,局部TED有效地治疗急性和
在兔体内和离体人角膜中的迟发型MGK,没有显著的副作用。我们的中央
假设是局部TED通过抑制SM诱导的早期MGK来治疗体内急性和延迟发作的MGK。
炎症反应,细胞外基质降解,以及过度促纤维化和促纤维化的产生。
无明显副作用的血管生成因子。该项目测试了两个新的假设,以建立一个
有效和安全的局部治疗急性和迟发型MGK在体内,使用四个特定的目标:目的-1
通过测试增加频率和持续时间的假设,
TED的应用将有效地治疗急性MGK和失明,而没有明显的副作用。Aim-2建立
通过检验低TED局部给药持续时间较长的假设,
持续时间将有效地治愈延迟发作的MGK,而不会在家兔中出现问题。Aim-3揭示了
TED在体内和体外缓解急性和延迟发作的MGK。Aim-4保护知识产权,
制定监管策略,并将TED局部滴眼液作为SM诱导的
对人类应用的眼损伤。这将使用已建立的SM-蒸汽家兔体内完成
和人角膜器官培养离体模型,GMP级TED滴眼液,以及活兔中的监测眼
以时间依赖的方式与临床眼科检查和诊断成像。的表征
TED用于缓解MGK的机制将使用安乐死后收集的角膜组织进行研究
测量角膜上皮基底膜、上皮基质组织和胶原纤维的完整性
使用qPCR、ELISA、免疫荧光、H&E和透射电子显微镜进行排列
利用我们公布的方法。该项目的成功完成将导致
急性和迟发性MGK的有效和安全的治疗方法,以及减少眼部损伤的医学对策
在人类中意外或故意使用SM导致的闭塞,因此将产生非常高的影响
在现场和公共安全。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rajiv Ravindra Mohan其他文献
Rajiv Ravindra Mohan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rajiv Ravindra Mohan', 18)}}的其他基金
BLR&D Research Career Scientist Award Application (Renewal)
BLR
- 批准号:
10618192 - 财政年份:2021
- 资助金额:
$ 74.04万 - 项目类别:
BLR&D Research Career Scientist Award Application (Renewal)
BLR
- 批准号:
10373048 - 财政年份:2021
- 资助金额:
$ 74.04万 - 项目类别:
Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur Mustard
涡轮滴眼液治疗硫芥引起的眼部毒性和失明
- 批准号:
10673584 - 财政年份:2020
- 资助金额:
$ 74.04万 - 项目类别:
Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur Mustard
涡轮滴眼液治疗硫芥引起的眼部毒性和失明
- 批准号:
10015700 - 财政年份:2020
- 资助金额:
$ 74.04万 - 项目类别:
Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur Mustard
涡轮滴眼液治疗硫芥引起的眼部毒性和失明
- 批准号:
10222708 - 财政年份:2020
- 资助金额:
$ 74.04万 - 项目类别:
Novel approaches for corneal haze/fibrosis elimination
消除角膜混浊/纤维化的新方法
- 批准号:
10431838 - 财政年份:2019
- 资助金额:
$ 74.04万 - 项目类别:
Novel approaches for corneal haze/fibrosis elimination
消除角膜混浊/纤维化的新方法
- 批准号:
10178035 - 财政年份:2019
- 资助金额:
$ 74.04万 - 项目类别:
Novel approaches for corneal haze/fibrosis elimination
消除角膜混浊/纤维化的新方法
- 批准号:
10005368 - 财政年份:2019
- 资助金额:
$ 74.04万 - 项目类别:
Targeted Gene Therapy and Nanomedicine Approaches to Treat Corneal Diseases
靶向基因疗法和纳米医学方法治疗角膜疾病
- 批准号:
9280757 - 财政年份:2009
- 资助金额:
$ 74.04万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 74.04万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 74.04万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 74.04万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 74.04万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 74.04万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 74.04万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 74.04万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 74.04万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 74.04万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 74.04万 - 项目类别:
Discovery Grants Program - Individual